Navigation Links
Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division
Date:2/8/2010

LAWRENCEVILLE, N.J., Feb. 8 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Michael H. Richardson has joined the company as Vice President, Commercial Operations for the newly formed Orphan Drug Business Unit. Donald A. Fishbein assumes the same role for the Ophthalmic Business Unit. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

Mr. Richardson holds responsibility of the company's orphan drug portfolio, which includes well-established specialty pharmaceuticals treating a range of rare and life-threatening conditions (Mephyton®, Edecrin®, Sodium Edecrin®, Cuprimine®, Syprine®, Demser®).  

Mr. Richardson possesses nearly 20 years of experience in pharmaceutical marketing, sales, product planning and business development. Prior to joining Aton, he was a Group Director of Marketing and Senior Director of Worldwide Product Planning for Cephalon. In those roles, Mr. Richardson was responsible for the successful launch of multiple products.

"With both product and corporate management experience, Michael Richardson brings tremendous commercial leadership to Aton Pharma," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is well rounded in all aspects of pharmaceutical marketing and preparing new products for launch. This experience will provide tremendous value to the company as we expand our orphan drug portfolio."

Prior to Cephalon, Mr. Richardson was a Director of Global Strategic Marketing at Johnson & Johnson where he worked on optimizing the life cycle of several strategic products. Also at Johnson & Johnson he served in New Product Planning. Prior to Johnson & Johnson, Mr. Richardson was in Sales for Merck & Co., Inc. He holds a B.A. degree in Chemistry from West Virginia University and a M.B.A. from the Fuqua School of Business at Duke University.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.

SOURCE Aton Pharma, Inc.

RELATED LINKS
http://www.atonrx.com

'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance
2. Octapharma Accepting Applications for Research Grants Through March 31
3. Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services
4. Possible pharmacological target(s) identified in pediatric OSA
5. Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010
6. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
7. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
8. Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
9. Pharmalink Regulatory Affairs Consulting Firm Opens New Offices in Washington, DC and Hartford, CT
10. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
11. Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent ... Gyrociser, an exercise invention which aids in proper muscle development. , "The Gym ... and Creative Director of World Patent Marketing. "Globalization has threatened the future growth ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... , April 28, 2016   Acsis , a ... that leading IT market research and advisory firm IDC ... the IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software ... report provides an assessment of the capabilities and business ... trace software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
Breaking Medicine Technology: